Attorney Docket No. 2472USOP DEC 1999

IN THE UNITED STATES PATENT AND THE

Applicants

s. HINUMA et al.

Serial No.

Attn. : Box PCT

Filed on

Title

Prolactin Secretion Modulator

INFORMATION DISCLOSURE STATEMENT


Assistant Commissioner for Patents Washington, D.C. 20231

Sir:

Pursuant to 37 C.F.R. 1.56, 1.97 and 1.98, applicants request consideration of (X) the references listed on the attached Form PTO-1449 and/or () the additional information identified below in paragraph 3. A legible copy of each reference listed on the Form PT-1449 is enclosed. 1

- 1. This Information Disclosure Statement is submitted:
 - a. (X)within 3 months of the filing date of the aboveidentified application, or () within 3 months of entry of the International Application, or () before the mailing date of the first Office Action on the merits, and thus no certification and/or fee is required.
 - b. ()after the events of above paragraph 1-a and prior to the mailing date of a final Office Action or Notice of Allowance, and thus:
 - ()the certification of paragraph ? below some provided, or
 - () a fee of \$.00 is enclosed(37 CFR 1.17(p)).

A copy is not provided for each reference previously cited by or submitted to the Patent Office in prior parent application Serial No._____.



2. It is hereby certified that:

- () each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the Statement, or
- () no item of information contained in the Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application and, to the knowledge of the person signing the certification after making reasonable inquiry, no item of information contained in the Information Disclosure Statement was known to any individual designated in § 1.56(c) more than three months prior to the filing of the Statement.
- 3.() Consideration of the following additional information (including any co-pending or abandoned U.S. application, prior uses and/or sales, etc.) is requested:
- 4. For each non-English language reference listed on the attached Form PTO-1449:
 - () reference is made to an English language translation submitted herewith, and/or
 - () reference is made to a foreign patent office search report (in the English language) submitted herewith, and/or
 - () reference is made to an English language translation of a foreign patent office search report submitted herewith, and/or
 - () reference is made to the concise explanation contained in the specification of the present application at page(s), and/or ()reference is made to the concise explanation attached thereto and/or



- () reference is made to the concise explanation set forth below:
- 5.() Applicants also offer the following comments for the Examiner's consideration:
- 6.(X) Also enclosed is a copy of:(X) the International Search Report citing these references, (X)the International Preliminary Examination Report, and (X)the Written Opinion.

Applicants respectfully request that the listed documents be considered by the Examiner and formally be made of record in the present application and that an initialed copy of Form PTO-1449 be returned in accordance with MPEP 9609.

Respectfully submitted,

Philippe Y. Riesen

Registration No. 35,657 Attorney for Applicants

C/O Takeda Chemical Industries, Ltd. 17-85 Jusohonmachi 2-chome

Yodogawa-ku, Osaka, Japan 532-8686

Phone #: 81-6-6300-6124
Fax #: 81-6-6300-6601

Date: December 15, 1999

428 Rec'd PCT/PTO 2 0 DEC 1999

Page 1 of 1										
FORM PTO 1449 (modified) U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE LIST OF REFERENCES CITED BY APPLICANT(S) (Use several sheets if necessary) Date Submitted to PTO:					y docket no 2US0P).: S	SERIAL NO.:			
					APPLICANT:					
					S. Hinuma et al.					
					NG DATE:	'	GROUP:			
The Control of the Co					T DOCUMENT	rs:				
*EXAMINER	REF	DOCUMENT	DATE		NAME	CLASS		FILING DATE IF		
INITIAL	No.	NUMBER						APPROPRIA'	I E	
						.	 	<u></u>		
						· .				
TEXTS LESS OF UPS SHOULD	You, 427 1950	Take British and The	် မှုလုံးများက	N.D'A	NENT DOCKBA	CNTS**			\$1284.680.T	
*EXAMINER	REF	DOCUMENT	DATE	C.	COUNTRY	CLASS	SUBCLASS	I TRANSLATI	ON II	
INITIAL	No.	NUMBER						YES N	0	
LM	Al	WO 96/05310	Feb. 22, 1		WIPO	•				
RM	A2	WO 97/24436	Jul. 10, 1997		WIPO					
RM RM RM	A3	WO 97/08317	Mar. 6, 1997		WIPO					
					-					
	-		<u> </u>			<u> </u>			1	
						!				
			<u> </u>			 			<u> </u>	
						 		-	-	
		1								
SECTION NAMED OF	1		OT	HER	DOCUMENT(S)			SAME STO	SAREVER	
*EXAMINER INITIAL	REF No.	AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.								
Rh	A4	T. Zheng et al., "Phenotypic characterization and functional correlation of" American J. of Physiology, (1997 Feb) 272 (2PT 1) £282-7, only abstract provided								
Rh	A5	G. Xie et al., "Expression cloning of cDNA encoding a seven" Proc. Natl. Acad. Scie. USA Vol. 89, pp. 4124-4128, (May 1992)								
Rh	A6	S. Hinuma et al., "A prolactin-releasing peptide in the brain" Nature (1998 May 21) 393 (6682) pp. 272-6								
101	A7	J. Buggy, "Binding of alpha-melanocyte-stimulating hormone" Biochemical Journal, (1998 Apr 1)								
Rh	171	(PT 1) pp. 211-6, only abstract provided								
Lh	A8	S. Sreedharan et al, "Cloning and functional expressio of" Biochem. Biopys. Res. Commun., vol. 193, no. 2, (June 15 1993) pp. 546-553								
EXAMINER:	RIT	A MITRA		D.	ATE CONSIDE	RED:	4/4/02			